Tim Opler, Ph.D.

Tim Opler, Ph.D.


New York Office

(212) 257-5802


Tim co-founded Torreya Partners in late 2007 and has a 15 year history of leading strategic and financing transactions in the life sciences industry. He has an active interest in diagnostics, nutritionals and pharmaceuticals. Over his career, Tim has completed more than 150 financing, licensing and M&A transactions with total value over $100 billion.

Prior to co-founding Torreya, he was VP, Strategy at FibroGen where he helped to raise $117 million for the company and helped to negotiate a licensing deal with Astellas for the European rights to the company’s Phase II anemia product. Before FibroGen, Tim was a Managing Director in the healthcare investment banking group at Credit Suisse First Boston where he managed relationships with a number of large pharmaceutical companies. Prior to joining Credit Suisse First Boston in 2001 Tim worked in senior roles at W.R. Hambrecht, Deutsche Bank and Merrill Lynch.

Tim leads Torreya Partners and has driven the spinout of Torreya Insights. Transaction work prior to Torreya includes running the largest share buyback in history for Pfizer (2003-2006); the sale of Chiron to Novartis (2006); carrying out a major structured transaction for GlaxoSmithKline (2005); leading a $3.9 billion convertible bond exchange for Amgen (2005); leading $2 billion in bond issuances for Eli Lilly (2005); managing Genentech’s inaugural $2 billion bond issue (2005); advising Pfizer on the sale of Heumann to Torrent (2005); leading a $365 million securitization and equity raise for Royalty Pharma (2004); working on a $400mm bond repurchase for Anthem (2004); advising Pfizer on the sale of Dorom and NM Pharma (2004); acting as a lead on Schering-Plough’s convertible bond issue (2004); managing $1.1bn in swaps and bond issues for Eli Lilly (2003); managing $150mm in derivatives for Guidant (2003); managing $850mm in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1bn bond issue (2002) and leading a $600mm Eurobond issue for Pfizer (2002). Prior to getting involved in life sciences industry investment banking Tim was also involved in advisory and transaction work for 3M, AMR, BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, Royal Dutch Shell, SBC, Toys R Us and Wal-Mart.

Before entering investment banking, Tim was a professor in the Finance Department at the Ohio State University, during which he authored more than a dozen scholarly articles on corporate finance. He earned a Ph.D. in Economics from UCLA and a B.S in Economics and Philosophy from Florida State University. While earning his Ph.D., Tim held a role as a statistical researcher at the RAND Corporation.

Tim is a registered representative with Financial West Group.